Breast cancer is characterized by the uncontrolled growth of
cancerous cells in the breast tissue. It occurs in both males and females;
however, male breast cancer is rare. Histologically, breast cancer can be
classified into ductal carcinoma, lobular carcinoma, nipple cancer and other
undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which
starts in the lining of the milk ducts while lobular carcinoma begins in the
milk glands of the breast. When breast cancer spreads from the site of origin
to surrounding tissue, it is known as invasive breast cancer. Invasive ductal
carcinoma is the most common subtype accounting for 70 to 80 percent of all the
breast cases. In women, breast cancer is the second most common form of cancer.
GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9
percent of the total cancer cases and lead to 5,22,000 deaths worldwide.
Analysts forecast the Global Breast
Cancer market will grow at a CAGR of 11.61 percent over the period
2014-2018.
Breast cancer is the leading cancer among women in both
developed and developing countries. Awareness programs and screening programs
can help in diagnosing potential cases of breast cancer, which otherwise remain
undetected till late stages. For instance, F. Hoffmann-La Roche runs a
Philippines centered Herceptin discount program, which has been reported to
provide benefit to 30 percent of treatment deprived cases. Similarly, F.
Hoffmann-La Roche launched a mobile breast cancer screening facility
"mammobile" in Algeria in 2013. Mammobile provides screening
facilities and healthcare professionals to remote regions of Algeria. Novartis
runs a pan-European advanced breast cancer campaign "Here & Now
project" to improve awareness of advanced breast cancer. Thus, the various
awareness programs are expected to enhance the market growth during the
forecast period.
Covered in this Report
This report covers the present scenario and the growth
prospects of the Global Breast Cancer market for the period 2014-2018. To
calculate the market size, the report considers revenue generated through the
sale of drugs used for the management of breast cancers including but not
limited to:
• HER2-negative breast cancer
• HER2-positive breast cancer
• Hormone receptor positive breast cancer
• Hormone receptor negative breast cancer
• Advanced breast cancer
• Early breast cancer
• Operable node positive breast cancer
• Metastatic breast cancer
• Triple Negative Breast Cancer
The report also presents the vendor landscape and a
corresponding detailed analysis of the top five vendors in the Global Breast
Cancer market. In addition, it discusses the major drivers that influence the
growth of the market. It also outlines the challenges faced by the vendors and
the market at large, as well as the key trends that are emerging in the market.
Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth
market analysis with inputs from industry experts. The report covers the
Americas, and the EMEA and APAC regions; it also covers the Global Breast
Cancer market landscape and its growth prospects in the coming years. The
report also includes a discussion of the key vendors operating in this market.
According to the report, one of the major drivers is the
increase in death rate because of breast cancer. The incidence and prevalence
rate of breast cancer is growing continuously, mainly because of the adoption
of sedentary forms of life and increased urbanization accompanied by increased
life expectancy. In 2012, the breast cancer mortality rate globally was 12.9
percent. In 2014, there were 40,000 breast cancer deaths in females and 430
breast cancer deaths in males in the US. Thus, an increased death rate because
of breast cancer might lead to more people opting for breast cancer treatment.
